Abstract
We report herein the discovery, structure guided design, synthesis and biological evaluation of a novel class of JAK2 inhibitors. Optimization of the series led to the identification of the potent and orally bioavailable JAK2 inhibitor 28 (NMS-P953). Compound 28 displayed significant tumour growth inhibition in SET-2 xenograft tumour model, with a mechanism of action confirmed in vivo by typical modulation of known biomarkers, and with a favourable pharmacokinetic and safety profile.
Keywords:
Anti-cancer agents; JAK2; Myeloproliferative disorders; Protein kinase inhibitor; Tumour cell proliferation inhibition.
Copyright © 2014 Elsevier Ltd. All rights reserved.
MeSH terms
-
Animals
-
Antineoplastic Agents / chemical synthesis
-
Antineoplastic Agents / chemistry
-
Antineoplastic Agents / pharmacology*
-
Cell Line, Tumor
-
Cell Proliferation / drug effects
-
Crystallography, X-Ray
-
Dose-Response Relationship, Drug
-
Drug Screening Assays, Antitumor
-
Humans
-
Janus Kinase 2 / antagonists & inhibitors*
-
Janus Kinase 2 / metabolism
-
Mice
-
Mice, SCID
-
Models, Molecular
-
Molecular Structure
-
Neoplasms, Experimental / drug therapy*
-
Neoplasms, Experimental / pathology
-
Protein Kinase Inhibitors / chemical synthesis
-
Protein Kinase Inhibitors / chemistry
-
Protein Kinase Inhibitors / pharmacology*
-
Pyrimidines / chemical synthesis
-
Pyrimidines / chemistry
-
Pyrimidines / pharmacology*
-
Pyrroles / chemical synthesis
-
Pyrroles / chemistry
-
Pyrroles / pharmacology*
-
Structure-Activity Relationship
-
Substrate Specificity
Substances
-
5-(2-aminopyrimidin-4-yl)-2-(2-chloro-5-(trifluoromethyl)phenyl)-1H-pyrrole-3-carboxamide
-
Antineoplastic Agents
-
Protein Kinase Inhibitors
-
Pyrimidines
-
Pyrroles
-
Janus Kinase 2